Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $38.50 Consensus Price Target from Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $38.50.

ALGS has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. Lake Street Capital assumed coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th.

Aligos Therapeutics Trading Up 4.8%

ALGS stock opened at $5.49 on Thursday. The firm has a market cap of $34.26 million, a PE ratio of -0.75 and a beta of 2.34. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69. The business’s 50-day moving average price is $5.78 and its two-hundred day moving average price is $6.16.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. The company had revenue of $27.78 million during the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, analysts forecast that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Several institutional investors have recently made changes to their positions in ALGS. Bank of America Corp DE boosted its stake in Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after acquiring an additional 216,646 shares during the last quarter. SummitTX Capital L.P. lifted its position in Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after buying an additional 9,375 shares during the last quarter. Renaissance Technologies LLC increased its stake in Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after purchasing an additional 15,006 shares during the period. Finally, Rockefeller Capital Management L.P. raised its position in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.

Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression.